TIDMEVG

RNS Number : 1731T

Evgen Pharma PLC

23 November 2021

Evgen Pharma plc

("Evgen Pharma" or "the Company")

Notice of results

Evgen Pharma plc (AIM: EVG), a clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases, announces it will issue its unaudited interim results for the six months ended 30 September 2021 on Tuesday, 7 December 2021.

Enquiries:

 
  Evgen Pharma plc www.evgen.com                                          via Walbrook 
  Dr Huw Jones, CEO 
  Richard Moulson, CFO 
 
  finnCap www.finncap.com                                          +44 (0)20 7220 0500 
  Geoff Nash / Teddy Whiley (Corporate 
   Finance) 
  Alice Lane (ECM) 
 
  Walbrook PR                             +44 (0)20 7933 87870 or evgen@walbrookpr.com 
                                                    +44 (0)7876 741 001 / + 44 (0)7867 
  Anna Dunphy / Phillip Marriage                                               984 082

About Evgen Pharma plc

Evgen Pharma is a clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases. The Company's core technology is Sulforadex(R), a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin.

Clinical data from the Company's open-label Phase II STEM trial has shown that SFX-01 can halt the growth of progressing tumours in patients with oestrogen-positive (ER+) metastatic breast cancer, and in some cases significantly shrink the tumour, whilst causing very few side effects.

The has its headquarters at Alderley Park, Cheshire, and its registered office is at the Liverpool Science Park, Liverpool. It is listed on the AIM market of the London Stock Exchange and trades under the ticker symbol EVG.

For further information, please visit: www.evgen.com

For research on the Company, please visit: http://evgen.com/investors/analyst-coverage/

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NORFEUFIEEFSEIF

(END) Dow Jones Newswires

November 23, 2021 02:00 ET (07:00 GMT)

Evgen Pharma (LSE:EVG)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024 Haga Click aquí para más Gráficas Evgen Pharma.
Evgen Pharma (LSE:EVG)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024 Haga Click aquí para más Gráficas Evgen Pharma.